<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Activity and Synergistic Effects with Oseltamivir against Influenza B Virus" exact="Infection" post="in the Mouse Model YangChunguang1WangYutao1HeJiayang1YanWen12JiangHaiming1ChenQiaolian1LiLi3https://orcid.org/0000-0002-2681-4171YangZifengjeffyah@163.com1[], 1[], 2[], 3 Academic"/>
 <result pre="Effects with Oseltamivir against Influenza B Virus Infection in the" exact="Mouse" post="Model YangChunguang1WangYutao1HeJiayang1YanWen12JiangHaiming1ChenQiaolian1LiLi3https://orcid.org/0000-0002-2681-4171YangZifengjeffyah@163.com1[], 1[], 2[], 3 Academic Editor: Mark Moss"/>
 <result pre="the main pathogens of the annual influenza epidemic, and the" exact="disease" post="burden is significant, especially among children and young teenagers."/>
 <result pre="orally administered Lianhua-Qingwen capsule (100â€&quot;400â€‰mg/kg/day) does not reduce IBV-induced lung" exact="viral" post="load and mortality in mice. However, the pathological change"/>
 <result pre="of Lianhua-Qingwen capsule with 2â€‰mg/kg/day of oseltamivir significantly reduced IBV" exact="infection" post="over the individual administration of either alone in vivo."/>
 <result pre="medicine to enhance the effect of oseltamivir against influenza B" exact="virus infection." post="Funding Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, China) National"/>
 <result pre="and Technology Department2013B051000085 Engineering Technology Research Center (Development) of Guangdong" exact="General" post="UniversitiesGCZX-A1408 Natural Science Basic Research Program of Shaanxi2019JM-513 1."/>
 <result pre="viruses (IAVs) in annual seasonal epidemics. The proportion of IBV" exact="infection" post="cases out of total influenza-positive cases varies from approximately"/>
 <result pre="seasonal epidemics. The proportion of IBV infection cases out of" exact="total" post="influenza-positive cases varies from approximately 1% to 40% in"/>
 <result pre="of IBV are weaker than those of IAV, but the" exact="disease" post="burden of IBV is significant, especially among children and"/>
 <result pre="LQ was approved for clinical trials as treatment for influenza" exact="infection" post="by the FDA in 2016. In addition, our previous"/>
 <result pre="Viruses and Cells Influenza B virus (B/Lee/40) was purchased from" exact="American" post="Type Culture Collection (ATCC; Manassas, VA, USA). B/Guangzhou/GIRD08/2009 (Victoria-like),"/>
 <result pre="by professor Malik J. S. Peilis (WHO Collaborating Centre for" exact="Infectious" post="Disease Epidemiology and Control, School of Public Health, Li"/>
 <result pre="professor Malik J. S. Peilis (WHO Collaborating Centre for Infectious" exact="Disease" post="Epidemiology and Control, School of Public Health, Li Ka"/>
 <result pre="LQ in IBVs was tested by cytopathic effect (CPE). Three" exact="infection" post="models were constructed. Before infection, 106 TCID50 of virus"/>
 <result pre="Pre-C). LQ was used to treat cells at 2â€‰h after" exact="infection" post="(posttreatment of virus, Post-V). The supernatant was collected at"/>
 <result pre="inoculated with B/Guangzhou/0215/2012 (MOIâ€‰=â€‰0.1) at 4Â°C for 2â€‰h, and the" exact="viral" post="solution was removed after washing twice with cold PBS."/>
 <result pre="added. The hemagglutination inhibition activity of LQ was defined in" exact="complete" post="inhibition of influenza virus hemagglutination activity after incubation for"/>
 <result pre="hemagglutination activity after incubation for 40â€‰min at room temperature. 2.8." exact="Viral" post="Binding Assay Next, 1â€‰Ã—â€‰103 cells were seeded in 24-well"/>
 <result pre="the cells were washed with cold PBS three times. The" exact="viral" post="binding was measured using an immunofluorescence assay. 2.9. Immunofluorescence"/>
 <result pre="LQ. The cells were collected at 24â€‰h after infection, the" exact="total" post="RNA was extracted using the TRIZOL reagent (Invitrogen), and"/>
 <result pre="7500 Real-Time PCR System [17]. 2.11. Animal Experiment Five-week-old, special-pathogen-free," exact="female" post="BALB/c mice were purchased from Guangdong Medical Laboratory Animal"/>
 <result pre="solution without virus. The drugs were administered at 4â€‰h before" exact="infection" post="and continued for 5 days once per day, with"/>
 <result pre="days after infection. To evaluate the effect of LQ on" exact="viral" post="yield in vivo, 30 mice (6 mice each in"/>
 <result pre="with oseltamivir alone or combined with LQ from 4â€‰h before" exact="infection" post="to 4 days after infection with the day of"/>
 <result pre="with LQ from 4â€‰h before infection to 4 days after" exact="infection" post="with the day of infection defined as 0 day,"/>
 <result pre="infection to 4 days after infection with the day of" exact="infection" post="defined as 0 day, and equivalent amounts of PBS"/>
 <result pre="were obtained by single-tailed Student's t-test when comparing two groups." exact="Multiple" post="group comparisons were performed via one-way ANOVA test based"/>
 <result pre="6â€‰h. This demonstrated that LQ inhibits the early stages of" exact="viral" post="cycle of IBV. 3.3. LQ Inhibits NP Replication of"/>
 <result pre="the effect of LQ on IBV replication, the synthesis of" exact="viral" post="nucleoprotein of infected cells was examined by immunofluorescence. The"/>
 <result pre="not A/California/04/2009. To confirm this result, indirect immunofluorescence microscopy of" exact="viral" post="binding was performed, and there was a similar result"/>
 <result pre="result (Figure 2(b)); that is, 0.6â€‰mg/mL of LQ could inhibit" exact="viral" post="binding to MDCK cells for B/Guangzhou/0215/2012 but not for"/>
 <result pre="B/Guangzhou/0215/2012 but not for A/California/04/2009. 3.5. LQ Displays Inhibition of" exact="Inflammatory" post="Cytokines and Chemokines after Influenza B Virus Infection in"/>
 <result pre="Inhibition of Inflammatory Cytokines and Chemokines after Influenza B Virus" exact="Infection" post="in mRNA Levels Inflammatory cytokine and chemokine expression imbalance"/>
 <result pre="and Chemokines after Influenza B Virus Infection in mRNA Levels" exact="Inflammatory" post="cytokine and chemokine expression imbalance will cause tissue damage."/>
 <result pre="IFN-Î»1 (113-fold) in the A549 cells at 12â€‰h after IBV" exact="infection" post="compared to GAPDH gene. Also, a reduction of all"/>
 <result pre="reduction. 3.6. LQ Reduces the Inflammation of Lungs in Mice" exact="Infection" post="Model To verify the treatment effect of LQ in"/>
 <result pre="tested at 15 days postinfection; the lung virus yield and" exact="lung inflammation" post="(pathological state) were tested at 6 days postinfection in"/>
 <result pre="that orally administered LQ (100â€&quot;400â€‰mg/kg/day) does not reduce IBV-induced lung" exact="viral" post="load and mortality in mice. However, the pathological change"/>
 <result pre="to uninfected mice (Figure 5(a)), untreated mice showed severe interstitial" exact="pneumonia" post="at 6 days after IBV infection (Figure 5(b)). In"/>
 <result pre="mice showed severe interstitial pneumonia at 6 days after IBV" exact="infection" post="(Figure 5(b)). In the positive control, ribavirin treated mice"/>
 <result pre="a few inflammatory cells around the terminal bronchus. Although interstitial" exact="pneumonia" post="was observed in 100â€&quot;400â€‰mg/kg/day of LQ treated mice (Figures"/>
 <result pre="treated mice lungs compared to the placebo group. 3.7. LQ" exact="Combined" post="with Oseltamivir in Infected Mice Model Displays Beneficial Effects"/>
 <result pre="of LQ and oseltamivir in IBV-infected mice was tested. The" exact="viral" post="titer in lungs (Figure 6) of infected mice treated"/>
 <result pre="LQ (200â€‰mg/kg/day) and oseltamivir (2â€‰mg/kg/day) (average valueâ€‰=â€‰log 3.67 TCID50/g) was" exact="lower" post="than the viral titer for mice treated with only"/>
 <result pre="oseltamivir (2â€‰mg/kg/day) (average valueâ€‰=â€‰log 3.67 TCID50/g) was lower than the" exact="viral" post="titer for mice treated with only LQ at dose"/>
 <result pre="oseltamivir at dose of 2â€‰mg/kg/day (average valueâ€‰=â€‰log 4.5 TCID50/g). Interestingly," exact="viral" post="load of 75â€‰mg/kg/day of ribavirin treated mice (average valueâ€‰=â€‰log"/>
 <result pre="75â€‰mg/kg/day of ribavirin treated mice (average valueâ€‰=â€‰log 3.17 TCID50/g) was" exact="lower" post="than that of 50â€‰mg/kg/day of oseltamivir (average valueâ€‰=â€‰log 3.67"/>
 <result pre="conjunction with 200â€‰mg/kg/day of LQ is better than oseltamivir alone." exact="Severe" post="interstitial pneumonia was observed in untreated mice (Figure 7(c)),"/>
 <result pre="200â€‰mg/kg/day of LQ is better than oseltamivir alone. Severe interstitial" exact="pneumonia" post="was observed in untreated mice (Figure 7(c)), 200â€‰mg/kg/day of"/>
 <result pre="50â€‰mg/kg/day of oseltamivir and 200â€‰mg/kg/day of LQ (Figure 7(d)). Moderate" exact="pneumonia" post="was observed in 10â€‰mg/kg/day of oseltamivir treated mice (Figure"/>
 <result pre="and 75â€‰mg/kg/day of ribavirin treated mice (Figure 7(b)), and mild" exact="pneumonia" post="was observed in mice treated simultaneously with 10â€‰mg/kg/day of"/>
 <result pre="oseltamivir and 200â€‰mg/kg/day of LQ (Figure 7(e)). Even though severe" exact="pneumonia" post="occurs in mice treated simultaneously with 2â€‰mg/kg/day of oseltamivir"/>
 <result pre="for anti-influenza B virus activity of LQ: (a) blockage of" exact="viral" post="binding to host receptors; (b) reduction of viral replication;"/>
 <result pre="blockage of viral binding to host receptors; (b) reduction of" exact="viral" post="replication; (c) reduction of inflammatory cytokines and chemokines storm"/>
 <result pre="assembly into vRNP in nucleus. In this study, NP was" exact="localized" post="by immunofluorescence staining. The results showed potent inhibitory effect"/>
 <result pre="virus (A/California/04/2009). To confirm this result, an immunofluorescence assay for" exact="viral" post="binding was performed, and the viral binding of B/Guangzhou/0215/2012"/>
 <result pre="an immunofluorescence assay for viral binding was performed, and the" exact="viral" post="binding of B/Guangzhou/0215/2012 to the MDCK cells surface was"/>
 <result pre="Also, influenza B virus HA binds to sialic acids with" exact="lower" post="affinity than influenza A virus [21]. We assumed that"/>
 <result pre="in the future. The cytokines and chemokines evoked by the" exact="infection" post="have been shown to contribute to the pathology associated"/>
 <result pre="been shown to contribute to the pathology associated with influenza" exact="virus infection" post="[22]. LQ is a combination of traditional Chinese medicines."/>
 <result pre="shown to contribute to the pathology associated with influenza virus" exact="infection" post="[22]. LQ is a combination of traditional Chinese medicines."/>
 <result pre="to antiviral activity, it may also have anti-inflammatory activity. Influenza" exact="virus infection" post="causes cell necrosis/apoptosis, which induces an immune reaction and"/>
 <result pre="antiviral activity, it may also have anti-inflammatory activity. Influenza virus" exact="infection" post="causes cell necrosis/apoptosis, which induces an immune reaction and"/>
 <result pre="and exaggerated production of cytokines, usually aggravates the degree of" exact="disease" post="[22]. Our results showed that LQ can inhibit the"/>
 <result pre="A virus, animal models for the study of influenza B" exact="infection" post="are lacking. This lack of studies is due to"/>
 <result pre="screened the clinical influenza B virus strains and obtained a" exact="stable" post="mouse lethal strain, B/Guangzhou/0215/2012 (B0215). In this study, the"/>
 <result pre="lethal strain, B/Guangzhou/0215/2012 (B0215). In this study, the data of" exact="viral" post="load in lungs and survival rates showed that orally"/>
 <result pre="of LQ through more indicators, such as fever, activity, and" exact="viral" post="load of upper respiratory in the future study. In"/>
 <result pre="more indicators, such as fever, activity, and viral load of" exact="upper" post="respiratory in the future study. In addition to effectiveness,"/>
 <result pre="indicators, such as fever, activity, and viral load of upper" exact="respiratory" post="in the future study. In addition to effectiveness, resistance"/>
 <result pre="chemical compounds, such as oseltamivir. Our results confirmed that the" exact="viral" post="titer in lungs of mice treated with LQ at"/>
 <result pre="LQ at 200â€‰mg/kg/day in combination with oseltamivir at 2â€‰mg/kg/day was" exact="lower" post="than that in mice treated with either LQ or"/>
 <result pre="in mice treated with either LQ or oseltamivir alone. The" exact="viral" post="load and inflammation in lungs of influenza B-infected mice"/>
 <result pre="Technology Department (2013B051000085), Engineering Technology Research Center (Development) of Guangdong" exact="General" post="Universities (GCZX-A1408), and Natural Science Basic Research Program of"/>
 <result pre="and hospitalization rates in a subtropical city, Hong Kong, 2000â€&quot;2010Clinical" exact="Infectious" post="Diseases201256567768423074315 2ThompsonW. W.MooreM. R.WeintraubE.et al.Estimating influenza-associated deaths in the"/>
 <result pre="Organization201290427928810.2471/blt.11.09695822511824 4MoonJ.-H.NaJ.-Y.KimJ.-H.et al.Neurological and muscular manifestations associated with influenza B" exact="infection" post="in childrenPediatric Neurology20134929710110.1016/j.pediatrneurol.2013.04.00423859854 5ThabetF. I.KhalilS.NazF.DymeI. Z.Cerebellar mutism and reversible"/>
 <result pre="with influenza B infection in childrenPediatric Neurology20134929710110.1016/j.pediatrneurol.2013.04.00423859854 5ThabetF. I.KhalilS.NazF.DymeI. Z.Cerebellar" exact="mutism" post="and reversible cytotoxic edema in influenza B-associated encephalopathyPediatric Neurology201349648949210.1016/j.pediatrneurol.2013.06.01424095574"/>
 <result pre="in influenza B-associated encephalopathyPediatric Neurology201349648949210.1016/j.pediatrneurol.2013.06.01424095574 6FrankH.WittekindC.LiebertU. G.et al.Lethal influenza B" exact="myocarditis" post="in a child and review of the literature for"/>
 <result pre="for pediatric age groupsInfection201038323123510.1007/s15010-010-0013-420358246 7PaddockC. D.LiuL.DenisonA. M.et al.Myocardial injury and" exact="bacterial pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
 <result pre="pediatric age groupsInfection201038323123510.1007/s15010-010-0013-420358246 7PaddockC. D.LiuL.DenisonA. M.et al.Myocardial injury and bacterial" exact="pneumonia" post="contribute to the pathogenesis of fatal influenza B virus"/>
 <result pre="the pathogenesis of fatal influenza B virus infectionThe Journal of" exact="Infectious" post="Diseases2012205689590510.1093/infdis/jir86122291193 8HaydenF. G.JenningsL.RobsonR.et al.Oral oseltamivir in human experimental influenza"/>
 <result pre="oseltamivir treatment among children with influenza A or B virus" exact="infections" post="during four successive winters in Niigata City, JapanThe Tohoku"/>
 <result pre="effectiveness of oseltamivir against influenza B contrasted with influenza A" exact="infection" post="in childrenClinical Infectious Diseases200744219720210.1086/50992517173216 12KawaiN.IkematsuH.IwakiN.et al.A comparison of the"/>
 <result pre="against influenza B contrasted with influenza A infection in childrenClinical" exact="Infectious" post="Diseases200744219720210.1086/50992517173216 12KawaiN.IkematsuH.IwakiN.et al.A comparison of the effectiveness of oseltamivir"/>
 <result pre="Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasonsClinical" exact="Infectious" post="Diseases200643443944410.1086/50586816838232 13GeH.WangY.-F.XuJ.et al.Anti-influenza agents from traditional Chinese medicineNatural Product"/>
 <result pre="prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of" exact="viral" post="propagation and impacts immune functionBMC Complementary and Alternative Medicine2017171p."/>
 <result pre="of influenza B virus in the reverse genetics eraJournal of" exact="General" post="Virology201192111710.1099/vir.0.026187-020926635 24GuanR.MaL.-C.LeonardP. G.et al.Structural basis for the sequence-specific recognition"/>
 <result pre="B virus infectionVirology Journal201916p. 7710.1186/s12985-019-1171-3 26HaydenF. G.Combination antiviral therapy for" exact="respiratory" post="virus infectionsAntiviral Research1996291454810.1016/0166-3542(95)00914-08721543 27DunningJ.BaillieJ. K.CaoB.HaydenF. G.Antiviral combinations for severe"/>
 <result pre="infectionsAntiviral Research1996291454810.1016/0166-3542(95)00914-08721543 27DunningJ.BaillieJ. K.CaoB.HaydenF. G.Antiviral combinations for severe influenzaThe Lancet" exact="Infectious" post="Diseases201414121259127010.1016/s1473-3099(14)70821-725213733 28BeigelJ. H.BaoY.BeelerJ.et al.Oseltamivir, amantadine, and ribavirin combination antiviral"/>
 <result pre="of influenza: a multicentre, double-blind, randomised phase 2 trialThe Lancet" exact="Infectious" post="Diseases201717121255126510.1016/s1473-3099(17)30476-028958678 29NguyenJ. T.SmeeD. F.BarnardD. L.et al.Efficacy of combined therapy"/>
 <result pre="of oseltamivir and ribavirin used alone and in combination against" exact="infections" post="in mice with recent isolates of influenza A (H1N1)"/>
 <result pre="Chemotherapy200617418519210.1177/09563202060170040317066897 31LiC.LiC.ZhangA. J.et al.Avian influenza A H7N9 virus induces severe" exact="pneumonia" post="in mice without prior adaptation and responds to a"/>
 <result pre="combination of N-acetylcysteine and ribavirin to protect from lethal influenza" exact="viral infection" post="in a mouse modelInternational Journal of Immunopathology and Pharmacology20041719910210.1177/03946320040170011415000873"/>
 <result pre="of N-acetylcysteine and ribavirin to protect from lethal influenza viral" exact="infection" post="in a mouse modelInternational Journal of Immunopathology and Pharmacology20041719910210.1177/03946320040170011415000873"/>
 <result pre="and Pharmacology20041719910210.1177/03946320040170011415000873 34Quispe-LaimeA. M.BraccoJ. D.BarberioP. A.et al.H1N1 influenza A virus-associated" exact="acute" post="lung injury: response to combination oseltamivir and prolonged corticosteroid"/>
 <result pre="vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09" exact="virus infection" post="in BALB/c miceClinical and Vaccine Immunology201421457057910.1128/cvi.00816-1324521786 36HaasbachE.HartmayerC.PlanzO.Combination of MEK"/>
 <result pre="expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus" exact="infection" post="in BALB/c miceClinical and Vaccine Immunology201421457057910.1128/cvi.00816-1324521786 36HaasbachE.HartmayerC.PlanzO.Combination of MEK"/>
 <result pre="and oseltamivir leads to synergistic antiviral effects after influenza A" exact="virus infection" post="in vitroAntiviral Research201398231932410.1016/j.antiviral.2013.03.00623523553 Figure 1 Influenza B virus yield"/>
 <result pre="oseltamivir leads to synergistic antiviral effects after influenza A virus" exact="infection" post="in vitroAntiviral Research201398231932410.1016/j.antiviral.2013.03.00623523553 Figure 1 Influenza B virus yield"/>
 <result pre="course assay: cells were treated with 0.6â€‰mg/mL of LQ after" exact="infection" post="with B0215 (MOIâ€‰=â€‰0.01); the supernatant was collected and titrated"/>
 <result pre="infected with B0215 at 0.1â€‰MOI for 90â€‰min at 4Â°C; the" exact="viral" post="solution was replaced with medium containing 1â€‰Î¼g/mL of TPCK"/>
 <result pre="performed at 8â€‰h after infection. Figure 2 LQ might target" exact="viral" post="binding activity of influenza B virus B0215. (a) Influenza"/>
 <result pre="Immunofluorescence assay for influenza B virus and influenza A virus" exact="viral" post="binding after treatment with 0.6â€‰mg/mL of LQ or the"/>
 <result pre="CCL2/MCP-1. (g) CCL4/MIP-1Î². (h) IFN-Î»1. Figure 4 The survival and" exact="viral" post="titer in lungs of B0215â€�infected mice after treatment with"/>
 <result pre="(a) Weight change after treatment. (b) Survival after treatment. (c)" exact="Viral" post="titer in lungs after treatment. The dotted line is"/>
 <result pre="Viral titer in lungs after treatment. The dotted line is" exact="limited" post="detection (LD). âˆ—P &amp;lt; 0.05 compared to placebo via"/>
 <result pre="200, and 400â€‰mg/kg/day of LQ, respectively (100x). Figure 6 The" exact="viral" post="load in lungs of B0215â€�infected mice treated with LQ"/>
 <result pre="infected mice lungs treated with LQ combined with oseltamivir after" exact="infection" post="with influenza B. (a) Uninfected. (b) Treated with 75â€‰mg/kg/day"/>
</results>
